Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection

References

• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280. e278.
   PubMed Web of Science ®Google Scholar
• Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–1448.
   PubMed Web of Science ®Google Scholar
• Li F, Li W, Farzan M, et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309:1864–1868.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.
   PubMed Web of Science ®Google Scholar
• Boni MF, Lemey P, Jiang X, et al. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. bioRxiv. 2020. doi:10.1101/2020.03.30.015008:2020.2003.2030.015008.
   PubMedGoogle Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. doi:10.1001/jama.2020.1585
   Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
   PubMed Web of Science ®Google Scholar
• Lurie N, Saville M, Hatchett R, et al. Developing covid-19 vaccines at pandemic speed. N Engl J Med. 2020. doi:10.1056/NEJMp2005630
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 - preliminary report. N Engl J Med. 2020. doi:10.1056/NEJMoa2007764
   Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study to describe the safety and Immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. medRxiv. 2020. doi:10.1101/2020.06.30.20142570:2020.2006.2030.20142570
   Google Scholar
• Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China. Lancet. 2003;362:1353–1358.
   PubMed Web of Science ®Google Scholar
• Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562–569.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 spike Glycoprotein. Cell. 2020;181:281–292. e286.
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454.
   PubMed Web of Science ®Google Scholar
• Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221–224.
   PubMed Web of Science ®Google Scholar
• Dinnon KH, Leist SR, Schafer A, et al. A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures. bioRxiv. 2020. doi:10.1101/2020.05.06.081497
   Google Scholar
• McCray PB J, Pewe L, Wohlford-Lenane C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81:813–821.
   PubMed Web of Science ®Google Scholar
• Tseng CT, Huang C, Newman P, et al. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human angiotensin-converting enzyme 2 virus receptor. J Virol. 2007;81:1162–1173.
   PubMed Web of Science ®Google Scholar
• Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020 doi:10.1038/s41586-020-2312-y..
   Web of Science ®Google Scholar
• Jiang RD, Liu MQ, Chen Y, et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell. 2020. doi:10.1016/j.cell.2020.05.027
   Web of Science ®Google Scholar
• Sun SH, Chen Q, Gu HJ, et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe. 2020. doi:10.1016/j.chom.2020.05.020
   Web of Science ®Google Scholar
• Israelow B, Song E, Mao T, et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. bioRxiv. 2020. doi:10.1101/2020.05.27.118893
   Google Scholar
• Hassan AO, Case JB, Winkler ES, et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell. 2020;182(3):744–753..e4.
   PubMed Web of Science ®Google Scholar
• Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals. bioRxiv. 2020. doi:10.1101/2020.05.22.111005
   Google Scholar
• Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382:2268–2270.
   PubMed Web of Science ®Google Scholar
• Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020. doi:10.1016/S2215-0366(20)30287-X
   Web of Science ®Google Scholar
• Coughlan L, Bradshaw AC, Parker AL, et al. Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Mol Ther. 2012;20:2268–2281.
   PubMed Web of Science ®Google Scholar
• Coughlan L, Vallath S, Saha A, et al. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J Virol. 2009;83:6416–6428.
   PubMed Web of Science ®Google Scholar
• Coughlan L, Vallath S, Gros A, et al. Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum Gene Ther. 2012;23:960–979.
   PubMed Web of Science ®Google Scholar
• Coughlan L. Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines. Front Immunol. 2020;11:909.
   PubMed Web of Science ®Google Scholar
• Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A. 2014;111:4970–4975.
   PubMed Web of Science ®Google Scholar
• Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79:14614–14621.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chirmule N, Gao GP, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther. 2001;3:697–707.
   PubMed Web of Science ®Google Scholar
• McInnes E. The respiratory system. In: Scudamore CL, editor. A practical guide to the histology of the mouse, 179–194. New York: John Wiley & Sons, Ltd; 2013.
   Google Scholar
• Zsengeller Z, Otake K, Hossain SA, et al. Internalization of adenovirus by alveolar macrophages initiates early proinflammatory signaling during acute respiratory tract infection. J Virol. 2000;74:9655–9667.
   PubMed Web of Science ®Google Scholar
• Mercier S, Gahery-Segard H, Monteil M, et al. Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product. J Virol. 2002;76:2899–2911.
   PubMed Web of Science ®Google Scholar
• Coughlan L, Alba R, Parker AL, et al. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses. 2010;2:2290–2355.
   PubMed Web of Science ®Google Scholar
• Yinda CK, Port JR, Bushmaker T, et al. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. bioRxiv. 2020. doi:10.1101/2020.08.11.246314
   Google Scholar
• Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–724.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020. doi:10.1126/science.abd4570
   Web of Science ®Google Scholar
• Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 Drives development of COVID-19. Cell. 2020;181:1036–1045. e1039.
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–2629.
   PubMed Web of Science ®Google Scholar
• Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92:791–796.
   PubMed Web of Science ®Google Scholar
• Roberts A, Vogel L, Guarner J, et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol. 2005;79:503–511.
   PubMed Web of Science ®Google Scholar
• Lamirande EW, DeDiego ML, Roberts A, et al. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol. 2008;82:7721–7724.
   PubMed Web of Science ®Google Scholar
• Imai M, Iwatsuki-Horimoto K, Hatta M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A. 2020. doi:10.1073/pnas.2009799117
   Web of Science ®Google Scholar
• Chan JF, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa325
   Web of Science ®Google Scholar
• Kulcsar KA, Coleman CM, Beck SE, et al. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019;4.
   PubMed Web of Science ®Google Scholar
• Yoshikawa N, Yoshikawa T, Hill T, et al. Differential virological and immunological outcome of severe acute respiratory syndrome coronavirus infection in susceptible and resistant transgenic mice expressing human angiotensin-converting enzyme 2. J Virol. 2009;83:5451–5465.
   PubMed Web of Science ®Google Scholar
• Yang XH, Deng W, Tong Z, et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. Comp Med. 2007;57:450–459.
   PubMed Web of Science ®Google Scholar
• Menachery VD, Yount BL Jr.,, Sims AC, et al. SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad Sci U S A. 2016;113:3048–3053.
   PubMed Web of Science ®Google Scholar
• Li K, Wohlford-Lenane C, Perlman S, et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J Infect Dis. 2016;213:712–722.
   PubMed Web of Science ®Google Scholar
• Sun J, Zhuang Z, Zheng J, et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell. 2020;182:734–743. e735. doi:10.1016/j.cell.2020.06.010
   PubMed Web of Science ®Google Scholar
• Case JB, Rothlauf PW, Chen RE, et al. Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host Microbe. 2020;S1931-3128(20):30421–30422.
   Google Scholar
• Winkler ES, Bailey AL, Kafai NM, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020. doi:10.1038/s41590-020-0778-2
   Web of Science ®Google Scholar
• Hassan AO, Kafai NM, Dmitriev IP, et al. A Single-dose intranasal Chad vaccine protects upper and lower respiratory Tracts against SARS-CoV-2. Cell. 2020;183:169–184. e113.
   PubMed Web of Science ®Google Scholar